Agents inhibiting the effect of estrogens and androgens are now routinely used to treat hormone receptor (ER-α and/or PgR)-positive breast cancer and prostatic cancer, respectively (Figure 5); however, accumulating preclinical and clinical studies have shown that some of them are promising as treatments against TNBCs. This evidence concerns the gene ESR1 and breast carcinoma.